Growth Metrics

Alto Neuroscience (ANRO) Change in Cash (2023 - 2026)

Alto Neuroscience has reported Change in Cash over the past 4 years, most recently at $87.3 million for Q1 2026.

  • Quarterly results put Change in Cash at $87.3 million for Q1 2026, up 1267.6% from a year ago — trailing twelve months through Mar 2026 was $103.0 million (up 330.75% YoY), and the annual figure for FY2025 was $8.3 million, down 90.42%.
  • Change in Cash reached $87.3 million in Q1 2026 per ANRO's latest filing, up from $38.7 million in the prior quarter.
  • Across five years, Change in Cash topped out at $123.3 million in Q1 2024 and bottomed at -$13.5 million in Q4 2024.
  • Median Change in Cash over the past 4 years was -$7.5 million (2025), compared with a mean of $16.6 million.
  • The largest annual shift saw Change in Cash plummeted 143.1% in 2024 before it skyrocketed 1267.6% in 2026.
  • Over 4 years, Change in Cash stood at $31.3 million in 2023, then crashed by 143.1% to -$13.5 million in 2024, then skyrocketed by 387.02% to $38.7 million in 2025, then skyrocketed by 125.71% to $87.3 million in 2026.
  • Business Quant data shows Change in Cash for ANRO at $87.3 million in Q1 2026, $38.7 million in Q4 2025, and -$9.8 million in Q3 2025.